ReviewMedicina (Kaunas, Lithuania)2024
Exploring Cognitive Deficits and Neuromodulation in Schizophrenia: A Narrative Review.
Review in Medicina (Kaunas, Lithuania), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Anodal tDCS over right DLPFC does not improve visuospatial working memory in schizophrenia: a single-session, sham-controlled study.BMC psychiatry · 2026Trial
- Beyond dopamine: KarXT and emerging mechanism-based therapies in schizophrenia.Frontiers in psychiatry · 2026Review
- ExoBDNF Probiotic Supplementation Enhances Cognition in Subjective Cognitive Decline.Medicina (Kaunas, Lithuania) · 2025Article
- Memory in Psychiatric Disorders: A Review.Life (Basel, Switzerland) · 2025Review
- Nucleus Reuniens-Elicited Delta Oscillations Disable the Prefrontal Cortex in Schizophrenia.Cells · 2025Review
- Visualizing functional network connectivity differences using an explainable machine-learning method.Physiological measurement · 2025Article
- Association of Exposure to Humidex with Schizophrenia Admissions in Qingdao, China: A Time-Series Study.Neuropsychiatric disease and treatment · 2025Article
- Biomarkers in schizophrenia - past, present and future.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Cognitive deficits are emerging as critical targets for managing schizophrenia and enhancing clinical and functional outcomes. These deficits are pervasive among individuals with schizophrenia, affecting various cognitive domains. Traditional pharmacotherapy and cognitive behavioral therapy (CBT) have limitations in effectively addressing cognitive impairments in this population. Neuromodulation techniques show promise in improving certain cognitive domains among patients with schizophrenia spectrum disorders. Understanding the mechanisms of neural circuits that underlie cognitive enhancement is essential for elucidating the pathophysiological processes of the disorder, and these insights could significantly optimize strategies for managing schizophrenia. Meanwhile, although there is an increasing body of evidence demonstrating the therapeutic effects of neuromodulation in this area, further research is still needed, particularly regarding topics such as different treatment protocols and the long-term effects of treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.